Skip to content

Study · Randomized controlled trial · n = 241 · 2017

3 results

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.

Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, Nilsson B, Møller JE, Hjort J, Rasmussen J, Boesgaard TW, Schou M and 5 more

Show all authors

Videbaek L, Gustafsson I, Flyvbjerg A, Wiggers H, Tarnow L

European journal of heart failure28 Oct 2016Cited by 477 (Europe PMC)

PMID27790809 (opens in a new tab)DOI10.1002/ejhf.657 (opens in a new tab)PepBankPUB-27790809
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with chronic heart failure and reduced LVEF, with and without type 2 diabetes, liraglutide did not change LVEF differently from placebo over 24 weeks.

    In plain wordsIn people with heart failure, liraglutide did not change heart pumping function differently from placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeChange in left ventricular ejection fraction (LVEF)
    Study

    n = 241

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg once daily · 24 weeksAs given in this study (human).

    Measurements

    Mean difference in LVEF change
    −0.8%
    liraglutide vs placebo

    Source sentences

    Summary
    Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was -0.8% (-2.1, 0.5; P = 0.24).
    2 context sentences
    Summary · context
    Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015).
    Summary · context
    Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks.
  2. 02HumanRandomized controlled trialSafety outcome

    In patients with chronic heart failure and reduced LVEF, liraglutide increased heart rate versus placebo.

    In plain wordsIn people with heart failure, liraglutide raised the heart rate more than placebo did.

    Peptide
    Liraglutide
    Outcome
    IncreaseHeart rate
    Study

    n = 241

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg once daily · 24 weeksAs given in this study (human).

    Measurements

    Mean difference in heart rate
    7 b.p.m.
    liraglutide vs placebo

    Source sentences

    Summary
    Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001].
    2 context sentences
    Summary · context
    Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015).
    Summary · context
    Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks.
  3. 03HumanRandomized controlled trialSafety outcome

    In patients with chronic heart failure and reduced LVEF, serious cardiac events were more frequent with liraglutide (12 patients, 10%) than with placebo (3 patients, 3%).

    In plain wordsIn people with heart failure, more serious heart events happened with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseSerious cardiac events
    Study

    n = 241

    Comparator
    Placebo
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    1.8 mg once daily · 24 weeksAs given in this study (human).

    Measurements

    Patients with serious cardiac events
    10%
    liraglutide
    Patients with serious cardiac events
    3%
    placebo

    Source sentences

    Summary
    Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P = 0.04).
    2 context sentences
    Summary · context
    Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015).
    Summary · context
    Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.